Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 13 Carcinoma, Non-Small-Cell Lung 8 Breast Neoplasms 7 Neoplasm Metastasis 6 Melanoma 5 Lymphoma, Non-Hodgkin 3 Lymphoma 3 Leukemia, Myeloid, Acute 3 Solid Tumor 2 Recurrence 2 Prostatic Neoplasms 2 Lung Neoplasms 2 Gastrointestinal Stromal Tumors 2 Colorectal Neoplasms 2 Carcinoma 2 Advanced Solid Tumor 2 Advanced Malignancies 2 cMET-dysregulated Advanced Solid Tumors 1 Urothelial Cancer 1 Thyroid Neoplasms 1 Synovitis, Pigmented Villonodular 1 Solid Tumours 1 Solid Tumour 1 Solid Tumors, KRAS Mutation 1 Solid Tumors 1 Solid Tumor, Adult 1 Sarcoma, Synovial 1 Sarcoma, Alveolar Soft Part 1 Sarcoma 1 Prostate Cancer Patients 1

Interventions

enzalutamide 5 Prednisone 5 cabazitaxel 4 Docetaxel 3 Abiraterone Acetate 3 fludrocortisone acetate 1 Zuclomiphene 1 XRP6258 1 Standard of Care 1 Prednisolone 1 Midazolam 1 LY3023414 1 Injections 1 Hydrocortisone 1 Dexamethasone 1 Abituzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Prostate Cancer Metastatic × Midazolam × Clear all

NCT03436485 2025-07-22

CYPIDES

Orion Corporation, Orion Pharma

Phase 1/2 Active not recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡